Article

Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum

2021-12-11

Abstract excerpt

In this report, we present live neutralisation titres against SARS-CoV-2 Omicron variant, compared with neutralisation against Victoria, Beta and Delta variants. Sera from day-28 post second-dose were obtained from participants in the Com-COV2 study who had received a two-dose COVID-19 vaccination schedule with either AstraZeneca (AZD1222) or Pfizer (BNT162b2) vaccines. There was a substantial fall in neutralisati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2856aac5-3802-5f58-a92e-071b92fbc483
DOI: 10.1101/2021.12.10.21267534

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serumDOI 10.1101/2021.12.10.21267534Read

Sub-optimal Neutralisation of Omicron (B.1.1.529) Variant by Antibodies induced by Vaccine alone or SARS-CoV-2 Infection plus Vaccine (Hybrid Immunity) post 6-monthsSemantic proximity Read

Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 VaccineSemantic proximity Read

Breadth of neutralising antibody responses to SARS-CoV-2 variants of concern is augmented by vaccination following prior infection: studies in UK healthcare workers and immunodeficient patientsSemantic proximity Read

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccinationSemantic proximity Read

Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2Semantic proximity Read

Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection historySemantic proximity Read

At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron VariantSemantic proximity Read

Three doses of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concernSemantic proximity Read

SARS-CoV-2 variants: levels of neutralisation required for protective immunitySemantic proximity Read

SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concernSemantic proximity Read

Neutralisation hierarchy of SARS-CoV-2 Variants of Concern using standardised, quantitative neutralisation assays reveals a correlation with disease severity; towards deciphering protective antibody thresholdsSemantic proximity Read

Development of a Novel Medium Throughput Flow-Cytometry Based Micro-Neutralisation Test for SARS-CoV-2 with Applications in Clinical Vaccine Trials and Antibody ScreeningSemantic proximity Read